CSB 2.006 Adding 5 Synthetic Cannabinoids to Schedule I.
CSB 2.007 Addition of ADB-BUTINACA, alpha-PiHP, and 3-MMC to Schedule I.
CSB 2.008 Addition of 2-Methyl AP-237 to Schedule I.
CSB 2.009 Addition of 2 Synthetic Benzimidazole-Opioids to Schedule I.
Ch. CSB 2 Note
Note:
Chapter CSB 2 (except CSB 2 (title)) was renumbered chapter CSB 2 Appendix under s. 13.92 (4) (b) 1., Stats.,
Register April 2023 No. 808. The appendix is printed at the end of this chapter and contains scheduling actions of the Controlled Substances Board prior to April 3, 2023, which used two-digit numbering ending with s. CSB 2.99. Scheduling actions on or after April 3, 2023, beginning with s. CSB 2.001, are printed below.
961.14 (7) (t) N-methyl-1-(thiophen-2-yl)propan-2-amine, commonly known as Methiopropamine.
CSB 2.001 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2023 No. 808, eff. 4-3-23.
CSB 2.002 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register April 2023 No. 808, eff. 4-17-23; correction made under s.
35.17, Stats.,
Register April 2023 No. 808.
CSB 2.003
CSB 2.003
Transfer of Flualprazolam and addition of 4 other synthetic Benzodiazepine substances to schedule I.
961.14 (5) (aa) Clonazolam (6-(2-chlorophenyl)-1-methyl-8-nitro-4 H -benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine).
(ab) Diclazepam (7-chloro-5-(2-chlorophenyl)-1-methyl-1,3-dihydro-2 H -benzo[ e][1,4]diazepin-2-one).
(ac) Etizolam (4-(2-chlorophenyl)-2-ethyl-9-methyl-6 H -thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine).
(ad) Flualprazolam (8-chloro-6-(2-fluorophenyl)-1-methyl-4 H -benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine).
(ae) Flubromazolam (8-bromo-6-(2-fluorophenyl)-1-methly-4 H -benzo[f][1,2,4]triazolo[4,3-a][1,4]diazepine).
CSB 2.003 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register September 2023 No. 813, eff. 9-25-23; correction in (2) made under s.
35.17, Stats.,
Register September 2023 No. 813.
961.20 (2) (r) Zuranolone.
CSB 2.004 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register February 2024 No. 818, eff. 2-5-24; correction in numbering of CSB 2.004 made under s.
13.92 (4) (b) 1., Stats.,
Register February 2024 No. 818.
CSB 2.005
CSB 2.005
Addition of 9 Fentanyl Related Substances to Schedule I.
961.14 (2) (nd) 3m. Alpha'-methyl butyryl fentanyl (2-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
10m. 2',5'-dimethoxyfentanyl (N-(1-(2,5-dimethoxyphenethyl)piperidin-4-yl)-N-phenylpropionamide);
11m. 3-furanyl fentanyl (N-(1-phenethylpiperidin-4-yl)-N-phenylfuran-3-carboxamide);
12e. Isovaleryl fentanyl (3-methyl-N-(1-phenethylpiperidin-4-yl)-N-phenylbutanamide);
12m. Meta-fluorofentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)propionamide);
12s. Meta-fluoroisobutyryl fentanyl (N-(3-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)isobutyramide);
16n. Ortho-fluorofuranyl fentanyl (N-(2-fluorophenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
17g. Para-methoxyfuranyl fentanyl (N-(4-methoxyphenyl)-N-(1-phenethylpiperidin-4-yl)furan-2-carboxamide);
17r. Para-methylcyclopropyl fentanyl (N-(4-methylphenyl)-N-(1-phenethylpiperidin-4-yl)cyclopropanecarboxamide);
CSB 2.005 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register February 2024 No. 818, eff. 2-5-24.
CSB 2.006
CSB 2.006
Adding 5 Synthetic Cannabinoids to Schedule I.
961.14 (4) (tb) 54. Methyl 3,3-dimethyl-2-(1-(pent-4-en-1-yl)-1H-indazole-3-carboxamido)butanoate, commonly known as MDMB-4en-PINACA.
55. Methyl 2-[[1-(4-fluorobutyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate, commonly known as 4F-MDMB-BUTICA or 4F-MDMB-BICA.
56. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-en-1-yl)-1H-indazole-3-carboxaminde, commonly known as ADB-4en-PINACA.
57. 5-Pentyl-2-(2-phenylpropan-2-yl)pyrido[4,3-b]indol-1-one, commonly known as CUMYL-PEGACLONE or SGT-151.
58. Ethyl 2-[[1-(5-fluoropentyl)indole-3-carbonyl]amino]-3,3-dimethyl-butanoate, commonly known as 5F-EDMB-PICA or 5F-EDMB-2201.
CSB 2.006 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register February 2024 No. 818, eff. 2-5-24.
CSB 2.007
CSB 2.007
Addition of ADB-BUTINACA, alpha-PiHP, and 3-MMC to Schedule I.
961.14 (4) (tb) 32m. N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyl-1H-indazole-3-carboxamide, commonly known as ADB-BUTINACA.
961.14 (7) (L) 2m. 3-methylmethcathinone or 2-(methylamino)-1-(3-methylphenyl)propan-1-one, commonly known as 3-MMC.
36m. 4-methyl-1-phenyl-2-(pyrrolidin-1-yl)pentan-1-one, commonly known as alpha-PiHP.
CSB 2.007 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register June 2024 No. 822, eff. 6-17-24; correction in (title) made under s.
13.92 (4) (b) 2., Stats.,
Register June 2024 No. 822.
961.14 (2) (qz) 2-methyl AP-237 (1-(2-methyl-4-(3-phenylprop-2-en-1-yl)piperazin-1-yl)butan-1-one);
CSB 2.008 History
History:
cr. Affirmative action order under s.
961.11 (4), Stats.,
Register June 2024 No. 822, eff. 5-20-24; correction made under s.
35.17, Stats.,
Register June 2024 No. 822.
961.14 (2) (xm) 7e. N-desethyl isotonitazene (N-ethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine).
961.14 (2) (xm) 7m. N-piperidinyl etonitazene also known as etonitazepipne (2-(4-ethoxybenzyl)-5-nitro-1-(2-(piperidin-1-yl)ethyl)-1H-benzimidazole).
CSB 2.009 History
History:
cr. Affirmative action order under s. 961.11 (4), Stats., Register October 2024 No. 826, eff. 10-21-24.
APPENDIX
CSB 2.009 Note
Note:
This Appendix contains actions of the Controlled Substances Board that were made prior to April 3, 2023, which were numbered ss.
CSB 2.01 to
2.99.
CSB 2.009 Note
CSB 2.01 Addition of methaqualone to schedule II. The substance known as methaqualone is hereby added to s.
161.16, Stats., schedule II in sub. (6) which subsection is hereby created.
CSB 2.009 History
History:
Cr.
Register, June, 1973, No. 210, eff. 7-1-73.
CSB 2.009 Note
CSB 2.02 Addition of benzphetamine, chlorphentermine, clortermine, mazindol, and phendimetrazine to schedule III. The
substances known as benzphetamine, chlorphentermine, clortermine, mazindol, and phendimetrazine are hereby added to s.
161.18, Stats., schedule III in sub. (2m) (a), (b), (c), (d) and (e) respectively, which subsections are created to read:
CSB 2.009 Note
(2m) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:
CSB 2.009 Note
(a) Benzphetamine
CSB 2.009 Note
(b) Chlorphentermine
CSB 2.009 Note
(c) Clortermine
CSB 2.009 Note
(d) Mazindol
CSB 2.009 Note
(e) Phendimetrazine
CSB 2.009 History
History:
Cr.
Register, October, 1973, No. 214, eff. 11-1-73.
CSB 2.009 Note
CSB 2.03 Addition of fenfluramine to schedule IV. The substance known as fenfluramine is hereby added to s.
161.20, Stats., schedule IV in sub. (2m) (a), which subsection is hereby created to read:
CSB 2.009 Note
(2m) Any material, compound, mixture, or preparation which contains any quantity of the following substances having a potential for abuse associated with a stimulant effect on the central nervous system:
CSB 2.009 Note
(a) Fenfluramine:
CSB 2.009 History
History:
Cr.
Register, October, 1973, No. 214, eff. 11-1-73.
CSB 2.009 Note
CSB 2.04 Addition of amobarbital, pentobarbital, and secobarbital to schedule II; retention of certain forms of amobarbital, pentobarbital and secobarbital in schedule III. (1) Subsection
(7) of s.
161.16, Stats., schedule II is hereby created to read as follows:
CSB 2.009 Note
(7) Unless excepted under federal regulations or listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances:
CSB 2.009 Note
(a) Amobarbital
CSB 2.009 Note
(b) Pentobarbital
CSB 2.009 Note
(c) Secobarbital
CSB 2.009 Note
(2) Paragraphs (m) and (n) of sub. (3), s.
161.18, Stats., schedule III, are hereby created to read as follows:
CSB 2.009 Note
(m) Unless excepted under federal regulations, any compound, mixture, or preparation containing amobarbital, secobarbital, pentobarbital or any salt thereof and one or more other active medicinal ingredients which are not listed in any schedule.
CSB 2.009 Note
(n) Unless excepted under federal regulations, any suppository dosage form containing amobarbital, secobarbital, pentobarbital, or any salt of any of these drugs and approved by the federal food and drug administration for marketing only as a suppository.
CSB 2.009 History
History:
Cr.
Register, July, 1974, No. 223, eff. 8-1-74.
CSB 2.009 Note
CSB 2.05 Addition of drotebanol to schedule I. The substance known as drotebanol is hereby added to s.
161.14, Stats., schedule I in sub. (3), par. (hm), which paragraph is created to read:
CSB 2.009 Note
(hm) Drotebanol;
CSB 2.009 History
History:
Cr.
Register, July, 1974, No. 223, eff. 8-1-74.
CSB 2.009 Note
CSB 2.06 Addition of pentazocine to schedule III. Subsection
(4m) of s.
161.18, Stats., schedule III is hereby created to read as follows: